This is a working overview of visceral fat, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-03 and is reviewed periodically as new material appears.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
=== Pharmacodynamics === Osemozotan acts as an agonist of the serotonin 5-HT1A receptor. It binds with almost 1,000 times greater affinity for the 5-HT1A receptor than for most other serotonin, dopamine, or adrenergic receptors. Even with repeated exposure of 5-HT1A receptors to osemozotan, there is no change in the number of receptors, unlike with other pharmaceutical agonists. It has been proposed that osemozotan could be used as an analgesic agent because of its activation of 5-HT1A receptors associated with an inhibitory serotonin-signaling pathway within the spinal cord which causes hypoalgesia and decreasing mechanical allodynia. Osemozotan was found to decrease the incidence of fighting in mice similar to buspirone, diazepam, and tandospirone but required a lower pharmacologic dose to produce beneficial effects. Osemozotan showed dose-dependent anti-aggressive effects and was not shown to decrease motor coordination in the mice. When stimulated, 5-HT1A receptors are shown to have anxiolytic and antidepressant pharmacologic effects. OCD patients have been found to have increased 5-HT levels in the brain. With the use of osemozotan as a 5-HT1A agonist, there is a decrease in serotonergic activity in the brain, leading to possible anti-obsessional pharmacological action. One animal mouse model used to test for OCD is known as the marble burying test, in which the amount of marbles buried within a certain time frame is recorded. Mice performed the marble burying test both with and without osemozotan.
==== Men's International friendly matches ==== 22 March – Ireland 3–2 Latvia. 21 November – Ireland 1–1 New Zealand. The Republic of Ireland team manager, Stephen Kenny, was fired from his position, after a three-year tenure, by the Football Association of Ireland the day after the match against New Zealand. His record as manager was 11 wins, 12 draws, and 17 defeats in 40 matches.
k¢ is the capacity factor of the solute KSW is the partition coefficient of the solute between the stationary phase and the water KMW is the partition coefficient of the solute between the micelles and the water f is the phase volume ratio (stationary phase volume/mobile phase volume) n is the molar volume of the surfactant CM is the concentration of the micelle in the mobile phase (total surfactant concentration - critical micelle concentration) A plot of 1/k¢ verses CM gives a straight line in which KSW can be calculated from the intercept and KMW can be obtained from the ratio of the slope to the intercept. Finally, KSM can be obtained from the ratio of the other two partition coefficients:
Sources: en.wikipedia.org
Pepino, a refreshing and thirst-quenching fruit, was eaten by common folk, but scorned by "pampered folk" and was considered difficult to digest. Another fruit that was available to the Incas was the passion fruit (Passiflora spp.) which was actually named so by the Spanish conquistadors and explorers due to the claim that the flowers of the plant contained the symbols of the passion of Christ. The fruit itself is like a pomegranate as they both have a mass of seeds covered by juicy flesh. A fruit that was described as an interesting snack available in the Andes during the time of the Inca Empire was the paqay (Inga feuilleei), or the guaba, which was known for its sweet, spongey substance that covers its seeds. A lesser valued fruit within Inca cuisine was the lúcuma (Lucuma bifera) which was difficult to consume and had little flavor. Opposite to the lucuma in popularity, due to their tender texture and the sweet juice they produce, were the almonds within Caryocar amygdaliferum of the Chachapoyas. They were luxury goods for many generations as many have been found within early tombs of the region.
{\displaystyle {\begin{array}{lll}M({\ce {NaCl}})&=[22.98976928(2)+35.453(2)]\times M_{\text{u}}\\&=58.443(2){\text{ g/mol}}\\M({\ce {C12H22O11}})&=[12\times 12.0107(8)+22\times 1.00794(7)+11\times 15.9994(3)]\times M_{\text{u}}\\&=342.297(14){\text{ g/mol}}\end{array}}}
=== The Commander === "The Commander" (Jack Farthing) is ostensibly an old friend of Henry's who shows up at his 40th birthday while an intoxicated Henry makes a scene before dinner guests. The Commander takes Henry to a pub where Henry spots his housekeeper Molly and her friend George; after George makes insulting comments about Yasmin, Henry viciously beats him at the Commander's provocation. The Commander is revealed to be Henry's hallucination of his late father, whose suicide on his own 40th birthday was witnessed by Henry as a child. Henry himself nearly attempts suicide the following morning in his father's vintage Jaguar E-Type via carbon monoxide poisoning, but relents at the last moment.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.